Figure 3.
Activation of FE11 γδTCR–transduced T cells is limited to HLA-A*24:0+malignant cells. (A) Activation of TEG011 cells by malignant and healthy hematological cells. B cells from multiple HLA-A*24:02+ donors were activated or stressed before the TEG011 cell coculture. (B) TEG011 or NEF134-144 αβTCR–engineered αβ T-cell recognition after coculture with HLA-A*24:02+ healthy tissues. When using NEF134-144 αβTCR–engineered αβ T cells, 10 μM NEF134-144 was added. (C) Healthy donor B cells (HD1) were EBV transformed and cocultured with TEG011. Recognition was assessed by measuring IFN-γ secretion using ELISA. Error bars represent the SD (n ≥ 2). *P < .05. Cyclo, cyclophosphamide; Fluda, fludarabine.

Activation of FE11 γδTCR–transduced T cells is limited to HLA-A*24:0+malignant cells. (A) Activation of TEG011 cells by malignant and healthy hematological cells. B cells from multiple HLA-A*24:02+ donors were activated or stressed before the TEG011 cell coculture. (B) TEG011 or NEF134-144 αβTCR–engineered αβ T-cell recognition after coculture with HLA-A*24:02+ healthy tissues. When using NEF134-144 αβTCR–engineered αβ T cells, 10 μM NEF134-144 was added. (C) Healthy donor B cells (HD1) were EBV transformed and cocultured with TEG011. Recognition was assessed by measuring IFN-γ secretion using ELISA. Error bars represent the SD (n ≥ 2). *P < .05. Cyclo, cyclophosphamide; Fluda, fludarabine.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal